Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
| 1.36 BATS BZX Real-Time Price As of 2:46pm ET |  -0.005 / -0.37%Today’s Change | 1.13 Today|||52-Week Range 4.62 | -51.18% Year-to-Date |
Latest MACK News | Press Releases
No recent news for Merrimack Pharmaceuticals Inc.
Today’s Trading
| Previous close | 1.36 |
| Today’s open | 1.36 |
| Day’s range | 1.35 - 1.36 |
| Volume | 8,545 |
| Average volume (3 months) | 2,744,516 |
| Market cap | $180.5M |
| Dividend yield | -- |
Data as of 2:46pm ET, 07/26/2017
Growth & Valuation
| Earnings growth (last year) | +9.02% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +5.61% |
| Revenue growth (last year) | +61.64% |
| P/E ratio | NM |
| Price/Sales | 3.54 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| RDHLRedhill Biopharma Lt... | +0.01 | +0.10% |
| ATHXAthersys Inc | 0.00 | 0.00% |
| ZYMEZymeworks Inc | -0.14 | -1.92% |
| MNOVMediciNova Inc | +0.05 | +0.94% |
Data as of 2:47pm ET, 07/26/2017
Financials
| Next reporting date | August 11, 2017 |
| EPS forecast (this quarter) | -$0.14 |
| Annual revenue (last year) | $144.3M |
| Annual profit (last year) | -$151.7M |
| Net profit margin | -105.18% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, CEO, CFO & Director Richard Peters |
Head- Corporate Operations William M. McClements |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
